Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Mylan Labs -- Ignore unavailable to you. Want to Upgrade?

To: J.K.B. who wrote (273)	4/6/1998 7:35:00 PM
From: David Lawrence	Read Replies (1) \| Respond to of 384

>>The letter stated that they would be removing MYLAN from their formulary. That's all well and good, if they have a viable alternative. Certainly the grapes aren't sour enough to cause them to remove it from the formulary if their only alternative is a higher priced name brand. They may be beating their chest in an attempt to get Mylan to back off, but I doubt that any benefit payors will choose to cut off their nose to spite their face over the issue. And the pharmacies - their inventory is driven by demand, not pricing preference. If they don't offer the generics, the consumer will simply have to take their business elsewhere, especially if generic is all their benefit provider will allow. Druggist - any comments? David